AXONIS Therapeutics

AXONIS Therapeutics is developing first-in-class therapies that enable neurons to resist degeneration, restore excitation/inhibition balance and regenerate, in order to rescue nervous system functions. Their lead drug candidate, an oral KCC2 (CNS-specific chloride transporter) enhancer, acts as a multi-modal neuromodul

AXONIS Therapeutics operates in neuro.

Profile

AXONIS Therapeutics is developing first-in-class therapies that enable neurons to resist degeneration, restore excitation/inhibition balance and regenerate, in order to rescue nervous system functions. Their lead drug candidate, an oral KCC2 (CNS-specific chloride transporter) enhancer, acts as a multi-modal neuromodulatory therapy for spinal cord injury, neuropathic pain and other neurological disorders.

Within the neuro space, the company focuses on its core offering rather than a broad product line.

Its current recorded stage is Creative Destruction Lab alumni company.

Website: axonis.us